My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 947

    1.

    Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.

    Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, Dixon ME, Polis AB, Mollen AJ, Geba GP; ADVANTAGE Study Group.

    Ann Intern Med. 2003 Oct 7;139(7):539-46.PMID: 14530224 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.

    Arch Intern Med. 2005 Jan 24;165(2):161-8. Erratum in: Arch Intern Med. 2005 Mar 14;165(5):551. PMID: 15668361 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.

    Watson DJ, Yu Q, Bolognese JA, Reicin AS, Simon TJ.

    Curr Med Res Opin. 2004 Oct;20(10):1539-48.PMID: 15462687 [PubMed - indexed for MEDLINE]Related articles

    4.

    Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.

    Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ.

    Arch Intern Med. 2000 Oct 23;160(19):2998-3003.PMID: 11041909 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.

    Watson DJ, Harper SE, Zhao PL, Bolognese JA, Simon TJ.

    MedGenMed. 2001 Nov 16;3(4):6.PMID: 11965201 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Summaries for patients. Gastrointestinal side effects of rofecoxib and naproxen.

    [No authors listed]

    Ann Intern Med. 2003 Oct 7;139(7):I29. No abstract available. PMID: 14530248 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.

    Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ; Alzheimer's Disease Cooperative Study.

    JAMA. 2003 Jun 4;289(21):2819-26.PMID: 12783912 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.

    Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J; Rofecoxib Rheumatoid Arthritis Endoscopy Study Group.

    Gut. 2003 Jun;52(6):820-6. Erratum in: Gut. 2003 Dec;52(12):1800. PMID: 12740337 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

    Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C.

    Gastroenterology. 2003 Feb;124(2):288-92.PMID: 12557133 [PubMed - indexed for MEDLINE]Related articles

    10.

    Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

    Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ.

    JAMA. 1999 Nov 24;282(20):1929-33.PMID: 10580458 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Rofecoxib for rheumatoid arthritis.

    Garner SE, Fidan DD, Frankish RR, Judd MG, Towheed TE, Wells G, Tugwell P.

    Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003685. Review.PMID: 15674912 [PubMed - indexed for MEDLINE]Related articles

    12.

    Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.

    Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.

    Health Technol Assess. 2008 Apr;12(11):1-278, iii. Review.PMID: 18405470 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.

    Goldstein JL, Bello AE, Spalding W, Suh S, Fort JG.

    J Rheumatol. 2005 Jan;32(1):111-7.PMID: 15630735 [PubMed - indexed for MEDLINE]Related articles

    14.

    Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.

    Hawkey C, Kahan A, Steinbrück K, Alegre C, Baumelou E, Bégaud B, Dequeker J, Isomäki H, Littlejohn G, Mau J, Papazoglou S.

    Br J Rheumatol. 1998 Sep;37(9):937-45. Erratum in: Br J Rheumatol 1998 Oct;37(10):1142. PMID: 9783757 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.

    JAMA. 2000 Sep 13;284(10):1247-55.PMID: 10979111 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.

    Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, Helgetveit KB, Kress B, Daniels B, Bolognese J, Krupa D, Seidenberg B, Ehrich E.

    Arch Intern Med. 2000 Jun 26;160(12):1781-7.PMID: 10871971 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.

    Baraf HS, Fuentealba C, Greenwald M, Brzezicki J, O'Brien K, Soffer B, Polis A, Bird S, Kaur A, Curtis SP; EDGE Study Group.

    J Rheumatol. 2007 Feb;34(2):408-20.PMID: 17304660 [PubMed - indexed for MEDLINE]Related articles

    18.

    Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.

    Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ.

    Circulation. 2001 Nov 6;104(19):2280-8.PMID: 11696466 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.

    Weir MR, Sperling RS, Reicin A, Gertz BJ.

    Am Heart J. 2003 Oct;146(4):591-604. Review.PMID: 14564311 [PubMed - indexed for MEDLINE]Related articles

    20.

    Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.

    Matheson AJ, Figgitt DP.

    Drugs. 2001;61(6):833-65. Review.PMID: 11398914 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity